Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHR285
MIFTS: 62

Chronic Myelomonocytic Leukemia

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases, Genetic diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Chronic Myelomonocytic Leukemia

About this section

MalaCards integrated aliases for Chronic Myelomonocytic Leukemia:

Name: Chronic Myelomonocytic Leukemia 38 12 76 53 59 29
Leukemia, Myelomonocytic, Chronic 53 73
Myelomonocytic Leukemia, Chronic 13
Leukemia Myelomonocytic Chronic 55
Cmml 59

Characteristics:

Orphanet epidemiological data:

59
chronic myelomonocytic leukemia
Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34 33
Orphanet: 59  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0080188
NCIt 50 C3178
Orphanet 59 ORPHA98823
UMLS via Orphanet 74 C0023480
ICD10 via Orphanet 34 C93.1
MESH via Orphanet 45 D015477
ICD10 33 C93.1
UMLS 73 C0023480
Sources

Summaries for Chronic Myelomonocytic Leukemia

About this section
Disease Ontology : 12 A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.

MalaCards based summary : Chronic Myelomonocytic Leukemia, also known as leukemia, myelomonocytic, chronic, is related to myelodysplastic myeloproliferative cancer and chronic neutrophilic leukemia, and has symptoms including fatigue, fever and night sweats. An important gene associated with Chronic Myelomonocytic Leukemia is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are cellular and growth/size/body region

Wikipedia : 76 Chronic myelomonocytic leukaemia (CMML) is a type of leukaemia, which are cancers of the blood-forming... more...

Sources

Related Diseases for Chronic Myelomonocytic Leukemia

About this section

Diseases in the Chronic Myelomonocytic Leukemia family:

Juvenile Myelomonocytic Leukemia

Diseases related to Chronic Myelomonocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 157)
# Related Disease Score Top Affiliating Genes
1 myelodysplastic myeloproliferative cancer 30.9 ASXL1 JAK2 SETBP1 TET2
2 chronic neutrophilic leukemia 30.6 ASXL1 SETBP1
3 refractory anemia with excess blasts 30.3 ASXL1 SETBP1 TET2
4 leukemia, acute lymphoblastic 29.8 ETV6 FLT3 RUNX1
5 juvenile myelomonocytic leukemia 29.8 DNMT3A FLT3 JAK2 PDGFRB RUNX1 SETBP1
6 splenomegaly 29.6 JAK2 SETBP1
7 mast cell disease 29.6 KIT PDGFRB TET2
8 refractory anemia 29.4 ASXL1 JAK2 RUNX1 TET2
9 atypical chronic myeloid leukemia 29.3 ASXL1 JAK2 RUNX1 SETBP1
10 leukemia 29.1 ETV6 FLT3 JAK2 KIT RUNX1
11 myeloid sarcoma 29.0 FLT3 KIT
12 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 28.9 ETV6 FLT3 KIT RUNX1
13 systemic mastocytosis 28.8 JAK2 KIT PDGFRB TET2
14 myeloproliferative neoplasm 28.7 JAK2 KIT PDGFRB TET2
15 lymphoblastic leukemia 28.4 ETV6 FLT3 JAK2 RUNX1
16 essential thrombocythemia 28.4 ASXL1 EZH2 JAK2 TET2
17 polycythemia vera 28.1 JAK2 KIT PDGFRB TET2
18 acute leukemia 27.7 ETV6 FLT3 JAK2 KIT RUNX1
19 myeloid leukemia 27.3 DNMT3A ETV6 FLT3 JAK2 KIT RUNX1
20 myelofibrosis 27.1 ASXL1 EZH2 FLT3 JAK2 KIT TET2
21 leukemia, chronic myeloid 26.4 ETV6 FLT3 JAK2 KIT PDGFRB RUNX1
22 myelodysplastic syndrome 26.2 ASXL1 DNMT3A ETV6 EZH2 FLT3 JAK2
23 leukemia, acute myeloid 25.2 ASXL1 DNMT3A ETV6 EZH2 FLT3 JAK2
24 pdgfrb-associated chronic eosinophilic leukemia 11.8
25 immunodeficiency 21 11.1
26 platelet disorder, familial, with associated myeloid malignancy 10.6 ETV6 RUNX1
27 b-cell childhood acute lymphoblastic leukemia 10.6 ETV6 RUNX1
28 primary hypereosinophilic syndrome 10.5 ETV6 PDGFRB
29 myeloproliferative disorder, chronic, with eosinophilia 10.5 ETV6 PDGFRB
30 myofibroma 10.4 ETV6 PDGFRB
31 sm-ahnmd 10.3 ASXL1 KIT
32 mn1 10.1 ETV6 FLT3
33 desmoid tumor 10.1 KIT PDGFRB
34 thrombocytopenia 10.1
35 congenital mesoblastic nephroma 10.1 ETV6 KIT
36 hypereosinophilic syndrome, idiopathic 10.1 KIT PDGFRB
37 leukemia, chronic lymphocytic 2 10.1
38 leukemia, chronic lymphocytic 10.1
39 hematopoietic stem cell transplantation 10.1
40 leukemia, b-cell, chronic 10.1
41 myeloma, multiple 10.0
42 lymphoma 10.0
43 sarcoma 10.0
44 histiocytosis 10.0
45 acute myeloblastic leukemia with maturation 10.0 FLT3 KIT
46 heart sarcoma 10.0 KIT PDGFRB
47 graft-versus-host disease 10.0
48 purpura 10.0
49 vasculitis 10.0
50 dendritic cell tumor 10.0

Graphical network of the top 20 diseases related to Chronic Myelomonocytic Leukemia:



Diseases related to Chronic Myelomonocytic Leukemia
Sources

Symptoms & Phenotypes for Chronic Myelomonocytic Leukemia

About this section

UMLS symptoms related to Chronic Myelomonocytic Leukemia:


fatigue, fever, night sweats

MGI Mouse Phenotypes related to Chronic Myelomonocytic Leukemia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 ETV6 ASXL1 EZH2 DNMT3A FLT3 PDGFRB
2 growth/size/body region MP:0005378 10.27 FLT3 ETV6 ASXL1 EZH2 DNMT3A PDGFRB
3 hematopoietic system MP:0005397 10.26 ASXL1 EZH2 DNMT3A FLT3 ETV6 KDM6A
4 endocrine/exocrine gland MP:0005379 10.25 ASXL1 EZH2 DNMT3A FLT3 ETV6 HIP1
5 homeostasis/metabolism MP:0005376 10.23 FLT3 ETV6 ASXL1 EZH2 DNMT3A KDM6A
6 immune system MP:0005387 10.21 ASXL1 EZH2 DNMT3A FLT3 ETV6 PDGFRB
7 mortality/aging MP:0010768 10.18 ETV6 ASXL1 EZH2 DNMT3A FLT3 PDGFRB
8 embryo MP:0005380 10.13 ETV6 EZH2 DNMT3A KDM6A KIT JAK2
9 cardiovascular system MP:0005385 10.09 ETV6 EZH2 KDM6A KIT TET2 PDGFRB
10 neoplasm MP:0002006 9.91 HIP1 ASXL1 EZH2 FLT3 ETV6 KIT
11 liver/biliary system MP:0005370 9.88 ASXL1 HIP1 KIT JAK2 TET2 RUNX1
12 muscle MP:0005369 9.8 EZH2 DNMT3A KDM6A HIP1 KIT PDGFRB
13 no phenotypic analysis MP:0003012 9.7 FLT3 ETV6 EZH2 KDM6A KIT TET2
14 normal MP:0002873 9.61 ETV6 EZH2 KDM6A HIP1 KIT JAK2
15 skeleton MP:0005390 9.28 FLT3 ASXL1 EZH2 KDM6A HIP1 KIT
Sources

Drugs & Therapeutics for Chronic Myelomonocytic Leukemia

About this section

Drugs for Chronic Myelomonocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
8
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
9
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
12
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
13
Ofloxacin Approved Phase 3 82419-36-1 4583
14
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
15
Idarubicin Approved Phase 3,Phase 1,Phase 2,Not Applicable 58957-92-9 42890
16
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
17
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
18
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
19
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 50-24-8 5755
21
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
22
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
23
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 4053 460612
24
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
25
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
26
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
27
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
28
Daunorubicin Approved Phase 3,Phase 1,Phase 2 20830-81-3 30323
29
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-02-2 5743
30
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
31
Thioguanine Approved Phase 3 154-42-7 2723601
32
Acyclovir Approved Phase 3 59277-89-3 2022
33
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
34
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
35
Ephedrine Approved Phase 3 299-42-3 9294
36
Pseudoephedrine Approved Phase 3 90-82-4 7028
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
38
Dalteparin Approved Phase 3 9005-49-6
39
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
40
Ondansetron Approved Phase 3,Phase 2,Phase 1,Not Applicable 99614-02-5 4595
41
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
42
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
43
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
44
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
45
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
46
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
47
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
48
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
49
Allopurinol Approved Phase 3,Phase 2,Phase 1 315-30-0 2094
50
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show top 50) (show all 469)
# Name Status NCT ID Phase Drugs
1 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
2 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
3 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
4 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
5 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
6 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
7 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
8 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
9 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
10 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
13 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
14 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
15 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
16 Decitabine Versus Supportive Care in Adults With Advanced-stage MDS Completed NCT00043381 Phase 3 decitabine (5-aza-2'deoxycytidine)
17 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
18 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
19 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
20 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
21 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
24 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
25 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
26 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
29 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
30 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
31 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
32 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
33 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
34 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Recruiting NCT03268954 Phase 3 Azacitidine;Pevonedistat
35 Study of ASTX727 vs IV Decitabine in MDS and CMML Recruiting NCT03306264 Phase 3 ASTX727;Dacogen
36 Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Recruiting NCT02214407 Phase 3 Decitabine;HYDROXYUREA
37 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Recruiting NCT02907359 Phase 3 Guadecitabine
38 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Recruiting NCT00619879 Phase 3 Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients;Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies
39 Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission Active, not recruiting NCT01757535 Phase 3 300 mg Oral Azacitidine;Placebo
40 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
41 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
42 Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Active, not recruiting NCT00843882 Phase 3 Lenalidomide
43 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
44 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3 caspofungin acetate;fluconazole
45 Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Terminated NCT00109538 Phase 3 Lonafarnib
46 Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis Terminated NCT01749111 Phase 3 ARM A Cyclophosphamide;ARM B Calcineurin inhibitor and methotrexate
47 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
48 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases Terminated NCT00450450 Phase 3
49 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
50 Lenalidomide in Patients With Chronic Myelomonocytic Leukemia Unknown status NCT01368757 Phase 1, Phase 2 Revlimid

Search NIH Clinical Center for Chronic Myelomonocytic Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Myelomonocytic Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Chronic Myelomonocytic Leukemia:
Hemacord
Embryonic/Adult Cultured Cells Related to Chronic Myelomonocytic Leukemia:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244
Sources

Genetic Tests for Chronic Myelomonocytic Leukemia

About this section

Genetic tests related to Chronic Myelomonocytic Leukemia:

# Genetic test Affiliating Genes
1 Chronic Myelomonocytic Leukemia 29
Sources

Anatomical Context for Chronic Myelomonocytic Leukemia

About this section

MalaCards organs/tissues related to Chronic Myelomonocytic Leukemia:

41
Myeloid, Bone, Bone Marrow, Monocytes, T Cells, Kidney, Liver
Sources

Publications for Chronic Myelomonocytic Leukemia

About this section

Articles related to Chronic Myelomonocytic Leukemia:

(show top 50) (show all 573)
# Title Authors Year
1
Chronic subdural collection overlying an intra-axial hemorrhagic lesion in chronic myelomonocytic leukemia: special report and review of the literature. ( 29658352 )
2018
2
Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia. ( 29707521 )
2018
3
Posaconazole-Induced Adrenal Insufficiency in a Case of Chronic Myelomonocytic Leukemia. ( 29568655 )
2018
4
So-called "blast phase" of chronic myelomonocytic leukemia: a plea for uniform terminology. ( 29955129 )
2018
5
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. ( 29728305 )
2018
6
A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN<sup>TM</sup>analyzers in routine laboratory practice. ( 29310473 )
2018
7
The 2016 WHO versus 2008 WHO Criteria for the Diagnosis of Chronic Myelomonocytic Leukemia. ( 29797820 )
2018
8
KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation. ( 29151134 )
2018
9
Chronic myelomonocytic leukemia with central nervous system involvement. ( 29322838 )
2018
10
Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. ( 29749401 )
2018
11
Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report. ( 29731877 )
2018
12
Characterization of chronic myelomonocytic leukemia with TP53 mutations. ( 29908419 )
2018
13
Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. ( 29582697 )
2018
14
Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. ( 29596070 )
2018
15
Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. ( 29878489 )
2018
16
CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia. ( 29600428 )
2018
17
Leukemia cutis in a patient with chronic myelomonocytic leukemia. ( 29288601 )
2018
18
Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis. ( 29757120 )
2018
19
Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms. ( 29891120 )
2018
20
Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia. ( 29227812 )
2018
21
EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental. ( 29358618 )
2018
22
The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. ( 29775844 )
2018
23
Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease. ( 29607228 )
2018
24
Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine. ( 29170809 )
2018
25
DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. ( 29160764 )
2018
26
Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia. ( 29368535 )
2018
27
Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective. ( 29588547 )
2018
28
A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. ( 29712989 )
2018
29
Exacerbation of mycosis fungoides leading to the diagnosis of chronic myelomonocytic leukemia. ( 29687069 )
2018
30
Blastic Transformation in Mexican Population With Chronic Myelomonocytic Leukemia. ( 28842140 )
2017
31
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. ( 28607470 )
2017
32
Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis. ( 28158286 )
2017
33
How I treat chronic myelomonocytic leukemia. ( 28572287 )
2017
34
Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article. ( 29069007 )
2017
35
Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. ( 28707414 )
2017
36
Genomic determinants of chronic myelomonocytic leukemia. ( 28555081 )
2017
37
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. ( 28548124 )
2017
38
Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. ( 29192651 )
2017
39
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. ( 28498370 )
2017
40
Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines. ( 29296739 )
2017
41
Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients. ( 28593791 )
2017
42
Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. ( 29262560 )
2017
43
Models of Prognostication in Chronic Myelomonocytic Leukemia. ( 29064026 )
2017
44
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. ( 28486043 )
2017
45
Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. ( 28905323 )
2017
46
Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. ( 28731458 )
2017
47
Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia. ( 29032731 )
2017
48
Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. ( 28885734 )
2017
49
Posttransplantation relapse of pediatric chronic myelomonocytic leukemia cured using donor lymphocyte infusion. ( 28895279 )
2017
50
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1. ( 28853315 )
2017
Sources

Variations for Chronic Myelomonocytic Leukemia

About this section

Copy number variations for Chronic Myelomonocytic Leukemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 160282 22 11800000 24300000 Translocation Chronic myelomonocytic leukemia
2 228217 7 75001344 75206215 Translate HIP1 Chronic myelomonocytic leukemia
3 247204 9 129300000 140273252 Translocation Chronic myelomonocytic leukemia
Sources

Expression for Chronic Myelomonocytic Leukemia

About this section
Search GEO for disease gene expression data for Chronic Myelomonocytic Leukemia.
Sources

Pathways for Chronic Myelomonocytic Leukemia

About this section

Pathways related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 37
Show member pathways
 12.48 FLT3 KIT PDGFRB RUNX1
2
Pathways in cancer 37
12.38 FLT3 JAK2 KIT PDGFRB RUNX1
3
Chromatin Regulation / Acetylation 4
12.08 DNMT3A EZH2 KDM6A TET2
4
Transcriptional misregulation in cancer 37
11.73 ETV6 FLT3 KDM6A RUNX1
5
VEGF Pathway (Tocris) 72
Show member pathways
 11.5 FLT3 KIT PDGFRB
6
Tyrosine Kinases / Adaptors 4
11.43 FLT3 JAK2 KIT PDGFRB
7
Central carbon metabolism in cancer 37
11.31 FLT3 KIT PDGFRB
8
Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex 1
10.14 DNMT3A ETV6 FLT3
Sources

GO Terms for Chronic Myelomonocytic Leukemia

About this section

Cellular components related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.4 ASXL1 DNMT3A ETV6 EZH2 FLT3 HIP1
2 receptor complex GO:0043235 9.13 FLT3 KIT PDGFRB

Biological processes related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.97 ETV6 FLT3 HIP1 JAK2 KIT PDGFRB
2 positive regulation of cell proliferation GO:0008284 9.9 FLT3 JAK2 KIT PDGFRB
3 positive regulation of cell migration GO:0030335 9.79 JAK2 KIT PDGFRB
4 positive regulation of protein kinase B signaling GO:0051897 9.76 HIP1 KIT PDGFRB
5 positive regulation of MAPK cascade GO:0043410 9.75 FLT3 KIT PDGFRB
6 negative regulation of signal transduction GO:0009968 9.73 FLT3 KIT PDGFRB
7 protein autophosphorylation GO:0046777 9.73 FLT3 JAK2 KIT PDGFRB
8 response to estradiol GO:0032355 9.71 DNMT3A EZH2 PDGFRB
9 peptidyl-tyrosine phosphorylation GO:0018108 9.71 FLT3 JAK2 KIT PDGFRB
10 positive regulation of kinase activity GO:0033674 9.69 FLT3 KIT PDGFRB
11 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.67 FLT3 JAK2 KIT PDGFRB
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 FLT3 JAK2 KIT
13 platelet-derived growth factor receptor signaling pathway GO:0048008 9.61 JAK2 PDGFRB
14 DNA methylation GO:0006306 9.59 DNMT3A EZH2
15 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.57 JAK2 PDGFRB
16 hemopoiesis GO:0030097 9.56 ASXL1 FLT3 KIT RUNX1
17 hematopoietic stem cell proliferation GO:0071425 9.55 ETV6 RUNX1
18 positive regulation of phospholipase C activity GO:0010863 9.52 KIT PDGFRB
19 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.5 FLT3 KIT PDGFRB
20 myeloid progenitor cell differentiation GO:0002318 9.46 FLT3 KIT
21 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.46 FLT3 JAK2 KIT PDGFRB
22 positive regulation of MAP kinase activity GO:0043406 9.26 EZH2 FLT3 KIT PDGFRB
23 chromatin organization GO:0006325 9.1 ASXL1 DNMT3A EZH2 JAK2 KDM6A TET2

Molecular functions related to Chronic Myelomonocytic Leukemia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.99 DNMT3A EZH2 FLT3 JAK2 KIT PDGFRB
2 protein kinase activity GO:0004672 9.8 FLT3 JAK2 KIT PDGFRB
3 chromatin binding GO:0003682 9.78 ASXL1 DNMT3A EZH2 KDM6A
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.58 JAK2 KIT PDGFRB
5 MAP kinase kinase kinase activity GO:0004709 9.5 FLT3 KIT PDGFRB
6 phosphatidylinositol 3-kinase binding GO:0043548 9.43 JAK2 PDGFRB
7 mitogen-activated protein kinase kinase binding GO:0031434 9.43 FLT3 KIT PDGFRB
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 FLT3 KIT PDGFRB
9 growth factor binding GO:0019838 9.13 FLT3 KIT PDGFRB
10 protein tyrosine kinase activity GO:0004713 8.92 FLT3 JAK2 KIT PDGFRB
11 protein binding GO:0005515 10.18 ASXL1 DNMT3A ETV6 EZH2 FLT3 HIP1
12 DNA binding GO:0003677 10 ASXL1 DNMT3A ETV6 EZH2 RUNX1 SETBP1
Sources

Sources for Chronic Myelomonocytic Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....